OOIR: Observatory of International Research

Papers

(The TQCC of Annals of the Rheumatic Diseases is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia	1006
Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumat	609
Short duration antibiotic therapy for native joint arthritis caused by Neisseria infection?	536
Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al	485
Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19	365
Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et al	340
Dysregulation of immune checkpoint molecules as a characteristic of autoimmune congenital heart block	338
POS1021 THE EFFECT OF CANNABIDIOL ON QUANTITATIVE SENSORY TESTING PARAMETERS IN PATIENTS WITH HAND OSTEOARTHRITIS AND PSORIATIC ARTHRITIS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL	324
POS1430 WATCH OUT FOR THE INFLAMMATORY RESPONSE IN AUTOIMMUNE DISEASES WITH INTERSTITIAL PNEUMONIA. A RETROSPECTIVE STUDY	315
AB0183 CARDIAC EFFECTS OF THE ARTHRITIS/HEART FAILURE COMORBIDITY	309
AB0160 THE USE OF IL-6 INHIBITORS IN PATIENTS WITH POLYMYALGIA RHEUMATICA RECEIVING GLUCOCORTICOID THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS	273
AB0073 ANTIBODY RESPONSE AND COVID-19 DISEASE AFTER SARS-CoV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES RECEIVING BIOLOGICAL TREATMENT	271
AB1331 DIAGNOSTIC CAPABILITY OF ANESTHETIC INTRA-ARTICULAR INJECTIONS FOR FEMOROACETABULAR IMPINGEMENT	250
AB1349 CORRELATION OF CHRONIC INFLAMMATION MARKERS WITH ULTRASOUND SIGNS OF ATHEROSCLEROTIC HEART DISEASE AND BRACHIOCEPHALIC ARTERIES LESIONS IN RHEUMATOID ARTHRITIS	244
AB1019 THE EFFECTS OF THREE DIFFERENT VITAMIN D3 SUPPLEMENTATION REGIMENS IN DEFICIENT SUBJECTS ON INFLAMMATORY CYTOKINES – A RANDOMISED OPEN-LABEL PARALLEL GROUPS STUDY	242
AB0795 Are patients with ankylosing spondylitis afraid of falling compared to healthy controls?: the role of balance and posture	231
AB0928 CHARACTERISTICS OF AXIAL PSORIATIC ARTHRITIS PATIENTS WITH SYMMETRICAL AND ASYMMETRICAL SACROILIITIS	221
AB0311 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS: FREQUENCY AND ASSOCIATED FACTORS	218
AB1025 TRABECULAR BONE SCORE IN PATIENTS WITH AXIAL-SPONDYLOARTHRITIS	214
AB0777 Influence of TNF inhibitors on subclinical atherosclerosis in Spondyloarthritis patients	206
AB1127 ANTIOSTEOPOROTIC TREATMENT AND COVID-19 RISK: IS THERE AN ASSOCIATION?	198
AB1134 BIBLIOMETRIC NETWORK ANALYSIS ON TOCILIZUMAB TREATMENT FOR COVID-19 PATIENTS	175
AB0878 Higher vitamin D serum level is associated with a better clinical response to bDMARDs in patients with axial spondyloarthritis.	173
AB0345 THERAPEUTIC DRUG LEVELS TO ACHIEVE GOOD EULAR RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB: RESULTS FROM THE BIOLOGICS IN RHEUMATOID ARTHRITIS GENETICS AND GENOMICS STUDY	173
POS1566-PARE BEYOND MEDICATION – SELF MANAGEMENT AS A COMPLEMENTARY APPROACH FOR TREATING RMDS	169

POS1526-HPR WHICH FACTORS INFLUENCE PATIENTS' PREFERENCES FOR TELEHEALTH APPLICATIONS IN RHEUMATIC DISEASES? A QUALITATIVE STUDY	166
POS0740 IMPACT OF TIME TO REMISSION, FLARES AND EXPOSURE TO IMMUNOSUPPRESSIVES ON THE DEVELOPMENT OF ADVANCED CHRONIC KIDNEY DISEASE (STAGE IV OR WORSE) IN LUPUS NEPHRITIS	162
OP0128 ADHERENCE TO MEDICATIONS DURING PREGNANCY IN SYSTEMIC AUTOIMMUNE DISEASE	160
POS0851 FREQUENCY OF METABOLIC SYNDROME AND ITS RELATIONSHIP WITH DISEASE CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS	156
AB0085 PRE-EXPOSURE PROPHYLAXIS OF SARS-COV-2 INFECTION AND SEVERE COVID-19 WITH TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN RHEUMATOLOGIC PATIENTS TREATED WITH RITUXIMAB AT RISK OF SEVERE COVID-19: EFFI	152
AB0102 DIFFERENTIAL EXPRESSION OF ORTHOLOGUE GENES INVOLVED IN GLYCINE AND PYRUVATE METABOLISM CHARACTERIZE THE GUT MICROBIOME META-TRANSCRIPTOME OF SUBJECTS WITH ASYMPTOMATIC HYPERURICEMIA AND GOUT	152
AB0068 LONG-TERM FOLLOW-UP OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE SAR-COVID REGISTRY	147
POS1537-HPR PERCEIVED BARRIERS AND FACILITATORS TO PHYSICAL ACTIVITY AND ITS ASSOCIATED FACTORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS	143
AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2	141
AB0294 VITAMIN D LEVEL AND LOCOMOTIVE FUNCTIONS IN WOMEN WITH RHEUMATOID ARTHRITIS	141
AB0273 IDENTIFICATION OF RED FLAGS FOR INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS	134
AB0526 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING SF-36 SCALE	130
POS1384 NON-INVASIVE IN VIVO METABOLIC PROFILING OF INFLAMMATION IN JOINTS AND ENTHESES BY OPTOACOUSTIC IMAGING	126
POS1338 CENTRAL SENSITIZATION AND RELATED FACTORS IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER	126
AB1040 ASSOCIATION OF Q141K POLYMORPHISM OF ABCG2 GENE WITH THE EFFECTIVENESS OF URATE-LOWERING THERAPY IN PATIENTS WITH GOUT (PILOT STUDY)	126
AB0347 TREATMENT RESPONSE WITH ABATACEPT PLUS METHOTREXATE TREATMENT FOR RHEUMATOID ARTHRITIS: REAL-WORLD EVIDENCE FROM THE UK	120
POS0619 CLINICAL AND SUBCLINICAL INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS: ASSOCIATED FACTORS.	118
POS0946 THE COURSE OF BONE MINERAL DENSITY DURING 8 YEARS OF TREATMENT WITH TNF-α INHIBITORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS	114
AB0963 Frequency of sexual dysfunction in psoriatic arthritis, Santo Domingo, Dominican Republic	113
AB0245 PULMONARY INVOLVEMENT IN RHEUMATOID ARTHRITIS AND SECONDARY SJÖGREN SYNDROME	110
OP0015 PROINFLAMMATORY MONOCYTES AND MACROPHAGES IN SYNOVIAL FLUID AND BURSAL TISSUE OF PATIENTS WITH POLYMYALGIA RHEUMATICA: POTENT PRODUCERS OF IL-6 AND GM-CSF	107
POS0405 INCREASED LEVELS OF CELLULAR ADHESION MOLECULES ARE LINKED TO THE PRESENCE OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH AUTOIMMUNE DISEASES	106
OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY	105
AB0032 ASSESSMENT OF AUTONOMIC DYSFUNCTION AND ITS RELATIONS WITH CLINICAL PARAMETERS IN FAMILIAL MEDITERRANEAN FEVER (FMF)	103
POS1087 THE RELATIONSHIP BETWEEN CHANGES IN PSORIATIC ARTHRITIS DISEASE ACTIVITY AND COMORBIDITIES IN PATIENTS TREATED WITH bDMARDs	101
POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS	100
OP0177 IMMUNOGENICITY INDUCED BY TWO AND THREE DOSES OF THE BNT162B2 mRNA VACCINE IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND IMMUNOCOMPETENT CONTROLS: A LONGITUDINAL MULTI-CENTER	99
POS0756 DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE (HR-QoL) ACROSS THE SPECTRUM OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE LEAP COHORT	98
POS0755 SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A SINGLE ORALLY ADMINISTERED DOSE OF ENPATORAN IN A PHASE I STUDY OF HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS	97
OP0208-HPR EFFECT OF AN 8-WEEK SPECIALIZED PHYSICAL THERAPY PROGRAM ON SEXUAL HEALTH IN FEMALE PATIENTS WITH SYSTEMIC SCLEROSIS AND IDIOPATHIC INFLAMMATORY MYOPATHIES: A PILOT STUDY	97
POS0846 MORTALITY OUTCOME OF ACUTE MYOCARDIAL INFRACTION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES, A QUALITATIVE APPROACH ANALYSIS OF THE NATIONAL INPATIENT SAMPLE FROM 2016-2019	94
POS0400 MODULATION OF HUMAN EARLY B CELL DEVELOPMENT THROUGH TARGETED DEGRADATION OF IKAROS AND AIOLOS WITH IBERDOMIDE	94
OP0055 THE COMPARISON OF EFFECTS OF TWO DIFFERENT EXERCISE PROGRAM ON FUNCTIONAL CAPASITY AND QUALITY OF LIFE IN PREGNANT WOMEN WITH LOW BACK PAIN	93
POS0452 ABNORMALITY OF TYPE I INTERFERON SIGNALLING IN B CELLS IN PRIMARY SJÖGREN´S SYNDROME AND THE IMPACT ON LABORATORY AND CLINICAL FINDINGS	92
POS0790 18F-FLUORODEOXYGLUCOSE (FDG) PET-CT IMAGING OF SALIVARY GLANDS IN PRIMARY SJÖGREN'S SYNDROME AND ITS CORRELATION WITH ULTRASONOGRAPHIC SCORES AND SALIVARY FLOW RATE COMPARED TO HEALTHY CONTROL	89
POS0730 A BETTER SELF-EFFICACY IS PREDICTIVE OF BETTER HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. DATA FROM A LATIN AMERICAN MESTIZO COHORT	89
POS0148 SPARCC, MASES, LEI AND MEI INDEXES CAPTURE DIFFERENT PATIENTS WITH ENTHESITIS IN AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS.	87
POS0984 PREVALENCE OF axSpA IN PATIENTS TREATED FOR CHRONIC BACK PAIN IN CHIROPRACTIC CLINICS: THE OREGON CHIROPRACTIC AXIAL SPONDYLOARTHRITIS STUDY (ORCAS) – AN INTERIM ANALYSIS	87
POS1066 DEVELOPMENT OF PHYSICAL AND MENTAL COMPONENT SUMMARY SCORES FROM PROMIS-29 INSTRUMENT IN PATIENTS WITH PSORIATIC ARTHRITIS	87
OP0080 STAT3 DEGRADERS INHIBIT Th17 DEVELOPMENT AND CYTOKINE PRODUCTION RESULTING IN PROFOUND INHIBITION OF COLLAGEN-INDUCED AUTOIMMUNE MURINE ARTHRITIS	86
POS0113 THE PREDICTIVE VALUE OF HEALTH LITERACY ON DISEASE ACTIVITY AND MEDICATION USE OVER TIME IN RHEUMATOID ARTHRITIS PATIENTS.	86
OP0132 PREVALENCE AND COMORBIDITIES OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN SPAIN: A RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORDS USING NATURAL LANGUAGE PROCESSING	86
POS0541 PREDICTORS OF REMISSION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH UPADACITINIB OR ADALIMUMAB IN THE SELECT-COMPARE PHASE 3 STUDY: CLINICAL STATUS AT WEEK 12, BUT NOT STANDARD LABORATORY ME	85
POS1540-HPR CENTRAL SENSITIZATION PLAYS A PROMINENT ROLE IN DISEASE ACTIVITY, FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE IN PATIENTS WITH SPONDYLOARTHRITIS.	83
AB1076 IS THERE AN ADDITIONAL IMPACT OF STIMULATING CD8+ LYMPHOCYTES TO DETECT LATENT TUBERCULOSIS IN PATIENTS WITH RHEUMATIC DISEASES?	83
POS0365 RELAPSES ARE COMMON ΙΝ SEVERE HEMATOLOGICAL SLE: REAL-LIFE EXPERIENCE FROM THE “ATTIKON” LUPUS COHORT	83
AB0230 THE INFLUENCE OF THE PATIENT'S PSYCHOLOGICAL STATUS ON THE INFLAMMATORY ACTIVITY OF RHEUMATOID ARTHRITIS	82
AB0240 CORRELATION BETWEEN KLOTHO LEVELS AND ANKLE-BRACHIAL INDEX IN FEMALE RHEUMATOID ARTHRITIS PATIENTS	82
AB1439 IS THERE AN INCREASED PREVALENCE OF DIABETES MELLITUS IN THE AXIAL SPONDYLOARTHROPATHY PATIENT GROUP: A REVIEW FROM A UK TEACHING HOSPITAL SPONDYLOARTHROPATHY SERVICE	81
AB0371 CLINICAL SIGNIFICANCE OF GALECTIN-3 IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE THE APPOINTMENT AND AFTER 12 MONTHS OF TREATMENT WITH BIOLOGICAL DRUGS (PRELIMINARY DATA).	81

AB0362 NEUTROPHIL COUNT REDUCTION 1 MONTH AFTER INITIATING SARILUMAB AND BASELINE SERUM SOLUBLE gp130 LEVELS CAN INDEPENDENTLY PREDICT CLINICAL REMISSION WITHIN 3 MONTH IN RHEUMATOID ARTHRITIS PATIENT	80
AB0764 Factors associated with remission after gradual decline of TNFi in spondyloarthritis	80
AB0229 ACHIEVING GLUCOCORTICOID FREE MIGHT DECREASE RISK FOR CLINICAL FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS - TEN-YEAR FINDINGS FROM THE TOMORROW STUDY	79
AB1012 MANAGEMENT OF BREAST CANCER TREATMENT INDUCED BONE LOSS- RE-AUDIT	79
AB1494 THE QUALITY OF REPORTING IN RANDOMIZED CONTROLLED TRIALS OF BALANCE EXERCISES IN TOTAL KNEE ARTHROPLASTY	79
AB0476 PREDICTIVE FACTORS FOR THE DEVELOPMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	79
AB1133 MUSCULOSKELETAL MANIFESTATIONS AMONG PATIENTS WITH COVID-19 INFECTION	77
AB1468 ALL-CAUSE MORTALITY IN PATIENTS WITH PALINDROMIC RHEUMATISM: A POPULATION-BASED COHORT STUDY	75
POS0718 SIROLIMUS MONOTHERAPY FOR THROMBOCYTOPENIA IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: A PILOT STUDY FROM A TERTIARY REFERRAL CENTER	74
Correction: Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial	73
Time to treat the climate and nature crisis as one indivisible global health emergency	72
POS1198 VACCINATION AGAINST COVID-19 SHOULD BE ENCOURAGED IN PATIENTS WITH RHEUMATIC DISEASE, AS MOST PATIENTS DEVELOP A SEROLOGICAL RESPONSE AGAINST THE VACCINE AND VACCINATION REDUCES SELF-IMPOSED I	72
POS1501-HPR ADDRESSING THE VOCATIONAL DEVELOPMENT OF YOUNG PEOPLE WITH LONG-TERM HEALTH CONDITIONS IN HEALTH CARE SETTINGS: A SYSTEMATIC REVIEW AND MIXED METHODS SYNTHESIS	71
POS1270 COVID19 VACCINATION IN PATIENTS WITH AXIAL AND PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: ADVERSE EVENTS AND IMPACT ON DISEASE ACTIVITY	71
POS1106 MEDIATORS OF THE EFFECT OF THERAPEUTIC EXERCISE ON PAIN AND FUNCTION IN PATIENTS WITH KNEE AND HIP OSTEOARTHRITIS; AN INDIVIDUAL PATIENT DATA MEDIATION STUDY FROM THE OA TRIAL BANK.	71
ABS0959 EVALUATION OF MULTIMODAL REHABILITATION AND ITS IMPACT ON COMORBIDITIES AND RISK FACTORS FOR THE TREATMENT OF KNEE PAIN AND IMPROVEMENT OF QUALITY OF LIFE IN EARLY OSTEOARTHRITIS: THE AKAPP ST	70
POS0848 REAL-WORLD CLINICAL CHARACTERISTICS AND PATTERNS OF CARE IN ADULTS WITH SJÖGREN'S DISEASE DIAGNOSED BY RHEUMATOLOGISTS VS NON-RHEUMATOLOGISTS: RETROSPECTIVE ANALYSIS OF US ELECTRONIC HEALTH RE	70
POS0527 Distinct cardiac phenotypes identified by cardiovascular magnetic resonance in treatment-naïve rheumatoid arthritis: a cluster analysis	70
POS1248 URIC ACID AND COVID-19: PATTERN OF CHANGES AND ASSOCIATION WITH PROGNOSIS	70
ABS0438 ASSOCIATIONS AND RISK FACTORS FOR FREQUENT ORAL ANALGESIC USE IN LOWER LIMB OSTEOARTHRITIS	69
ABS0950 ARTIFICIAL INTELLIGENCE ANALYSIS OF HRCT IMAGES REFLECTS PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE	68
POS1433 N-ACETYL-SERYL-ASPARTYL-LYSYL-PROLINE (AcSDKP) IN RHEUMATOID ARTHRITIS: A NOVEL BIOMARKER FOR DISEASE ACTIVITY AND THERAPEUTIC MONITORING	68
ABS0887 VASCULOPATHY RATHER THAN SKIN FIBROSIS AS A PREDICTOR OF HAND FUNCTION WORSENING IN SYSTEMIC SCLEROSIS PATIENTS	68
POS0953 VASCULAR DAMAGE IS LESS PRESENT IN AN EARLY INCEPTION COHORT IN TAKAYASU'S ARTERITIS	67
OP0036 Artificial Intelligence Reinforced Social Robotics in Patient Communication for Patients with Rheumatic Diseases	67
ABS1196-HPR HIGH REPORT OF SIDE-EFFECTS, AND ASSOCIATION OF PATIENTS' AGE WITH TOLERANCE OF SUBCUTANEOUS METHOTREXATE – TELEPHONE SURVEY RESULTS FROM A QUALITY IMPROVEMENT PROJECT	66
ABS1173-HPR EVALUATION OF A PHARMACIST-LED MEDICATION ADHERENCE CLINIC FOR RHEUMATOLOGY PATIENTS PRESCRIBED DMARDS	66
OP0270 SENSITIVITY OF THE ACR/EULAR CLASSIFICATION CRITERIA IN A MULTICENTER ITALIAN COHORT OF PATIENTS WITH OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (OAPS): IMPLICATIONS FOR CLINICAL PRACTICE	66
POS1038 HIGH PREVALENCE OF INFLAMMATORY PsA-SPECIFIC FINDINGS IN PATIENTS WITH LONG-STANDING PSORIASIS BUT NO MUSCULOSKELETAL SYMPTOMS	66
POS0985 CROSS CULTURAL VALIDATION OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE IN LUPUS PATIENTS FROM LATIN AMERICA	66
POS0656 TOLERABILITY AND EFFICACY OF BMS-986353 (CC-97540), A CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY MANUFACTURED USING A NEXT-GENERATION PROCESS FOR SYSTEMIC SCLEROSIS: UPDATED	66
OP0275 POTENTIAL DRUG TARGETS FOR CHRONIC WIDESPREAD PAIN: A PROTEOME-WIDE MENDELIAN RANDOMIZATION AND DRUG REPURPOSING ANALYSIS	66
ABS0290 LIFE SATISFACTION AND MEDICATION ADHERENCE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CROSS-SECTIONAL ANALYSIS OF ELLES COHORT BASELINE DATA	65
POS1402 NEXT GENERATION CAR-NK CELL THERAPY LEVERAGES ALLOIMMUNE DEFENSE TECHNOLOGY TO PERSIST WITHOUT CONDITIONING CHEMOTHERAPY FOR THE TREATMENT OF AUTOIMMUNE DISEASE	65
OP0081 Anti-Ro/SSA+/RF+ double seropositivity in systemic sclerosis is associated with more severe interstitial lung disease: A study from the EUSTAR database	65
POS0695 SHIFT TOWARDS IgA EXPRESSION AND ABERRANT B CELL RECEPTOR SIGNALING RESPONSES IN DOUBLE NEGATIVE B CELLS FROM PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS	64
Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?	64
POS0634 ASSOCIATION OF RADIOLOGICAL FINDINGS OF THE HAND WITH HAND FUNCTION AND AUTOANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS	64
POS0813 CAR T-CELL THERAPY IN SLE: A SYSTEMATIC/SCOPING REVIEW	63
POS1091 Development and Validation of ‘Rheumatic ‘ - A Digital Symptom Checker for Confirmation and Prediction of Rheumatic Diseases: A Large-Scale Prospective Study	63
POS1334 ACHIEVEMENT OF PROTEINURIA TARGETS =0.4 g/g IN LUPUS NEPHRITIS: A POST HOC ANALYSIS OF THE AURORA 1 STUDY OF VOCLOSPORIN	62
POS1511-HPR PHYSICAL FITNESS AND FUNCTIONAL CAPACITY IN CHILDREN AND ADOLESCENTS WITH JUVENILE DERMATOMYOSITIS	62
ABS0439 PATH TO DIAGNOSIS IN FAMILIAL MEDITERRANEAN FEVER (FMF)	62
ABS1200-HPR A MULTICENTRIC CROSS SECTIONAL STUDY EVALUATING THE BONE HEALTH IN YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	61
ABS0378 PROGRESSIVE OSSIFYING FIBRODYSPLASIA AS A VARIANT OF AXIAL SPONDYLOARTHRITIS WITH JUVENILE ONSET	60
POS0878 A PATIENT WITH MENTAL HEALTH DISORDER IN CONSULTATION: WHAT ARE THE ATTITUDES OF RHEUMATOLOGISTS	60
POS0721 INTERPRETATION OF ANTI-NUCLEAR ANTIBODY INDIRECT IMMUNOFLUORESCENCE PATTERNS USING ARTIFICIAL INTELLIGENCE	60
ABS0931 SLEEP QUALITY IN SYSTEMIC LUPUS ERYTHEMATOSUS: COMPARISON OF OBJECTIVE AND SUBJECTIVE SLEEP ASSESSMENT METHODS	60
POS0704 LIPIDOMICS AND INFLAMMATION FOLLOWING DISEASE ONSET IN NEWLY DIAGNOSED RHEUMATOID ARTHRITIS: INSIGHTS FROM THE DESIGNA (DIETARY SIGNATURES IN ARTHRITIS) STUDY	60
OP0333 INITIAL THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE	60
ABS0110 INTEGRATIVE OMICS REVEALS MOLECULAR SIGNATURES DISTINGUISHING EARLY FROM ESTABLISHED RHEUMATOID ARTHRITIS AND PREDICTING CLINICAL RESPONSE	59
POS1376 SPUTUM CALPROTECTIN LEVELS DO NOT ADD TO ABILITY OF SPUTUM ANTI-CCP AND RF TO PREDICT FUTURE DEVELOPMENT OF RA IN SERUM ANTI-CCP POSITIVE INDIVIDUALS AT-RISK FOR RA	59
ABS0357 EVALUATION OF THE UTILITY OF PHASE ANGLE IN THE DIAGNOSIS OF RHEUMATOID SARCOPENIA	58
POS1458-HPR EFFECTIVENESS OF A BIOPSYCHOSOCIAL-BASED EXERCISE APPROACH ON PATIENT OUTCOMES IN PRIMARY SJÖGREN'S SYNDROME: A PRELIMINARY RANDOMIZED CONTROLLED TRIAL	58
POS1216 EFFECT OF GENDER AND FOLLOW-UP TIME IN DAMAGE ACCRUAL: DATA FROM A LATIN AMERICA LUPUS COHORT	58
ABS0060 UNDERSTANDING DRIVERS OF LUPUS PATHOGENESIS THROUGH COMPARISON OF PRECLINICAL MODELS	57
ABS0310 IMPACT OF ANTI-CITRULLINATED PROTEIN ANTIBODIES ON TNF INHIBITOR AND JAK INHIBITOR PRESCRIPTIONS IN RHEUMATOID ARTHRITIS: CROSS-SECTIONAL STUDIES FROM THE ART AND MAJIK REGISTRIES	57
POS0242 MECHANICAL FORCES TRIGGER INVASIVE BEHAVIOUR IN SYNOVIAL FIBROBLASTS THROUGH N-CADHERIN/ADAM15-DEPENDENT MODULATION OF lncRNA H19 IN RHEUMATOID ARTHRITIS	57
OP0215 SPATIAL TRANSCRIPTOMICS OF SKIN BIOPSIES FROM VERY EARLY SYSTEMIC SCLEROSIS UNVEILS EARLY DRIVERS OF SKIN FIBROSIS WITHIN THE EPIDERMIS	56
ABS0343 SUBCUTANEOUS ULTRA-LOW DOSE RITUXIMAB VERSUS INTRAVENOUS ULTRA-LOW DOSE RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL	56
OP0372-PARE Beyond the Doctor's Office: The School and Workplace Needs of Young People Living with Rheumatic Disease	56
POS0228 PROTEIN PROFILING TO IDENTIFY INFLAMMATORY MARKERS ASSOCIATED WITH FERTILITY IN RA; AN EXPLORATORY STUDY	56
ABS0015 SKIN MICROBIOME SHOWS DIFFERENCES BETWEEN PATHERGY POSITIVE AND NEGATIVE PATIENTS WITH BEHÇET'S SYNDROME	55
ABS0542 PARAPROTEINEMIAS IN SJÖGREN'S DISEASE: ISOLATED MONOCLONAL GAMMOPATHY AND CRYOGLOBULINEMIA DEFINE TWO DISTINCT DISEASE PHENOTYPES	55
POS1066 AN ALTERED IMMUNOMETABOLIC PROFILE CHARACTERIZES B CELLS OF PATIENTS WITH OLIGOARTICULAR- AND POLYARTICULAR- JUVENILE IDIOPATHIC ARTHRITIS	55
ABS1063 THE MANY FACES OF WHIPPLE'S DISEASE	55
ABS0639 CLINICAL CHARACTERISTICS OF PHYSICAL FRAILTY IN PATIENTS WITH SYSTEMIC SCLEROSIS: AN ANALYSIS USING A JAPANESE SINGLE-CENTER COHORT	54
ABS0047 MATERNAL AND NEONATAL ANTI-RO52, ANTI-RO60 AND ANTI-LA LEVELS CORRELATE WITH INTERFERON SCORES	54
ABS0291 CLINICAL AND HEMODYNAMICS OUTCOMES PATIENTS WITH PULMONARY HYPERTENSION AND SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES	54
ABS0665 CORRELATION BETWEEN Ro52 ANTIBODY POSITIVITY AND ELECTROCARDIOGRAPHIC ALTERATIONS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY	54
ABS0350 LONG-TERM CHANGES IN PARAMETERS OF BONE QUALITY IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH DENOSUMAB	53
POS0068 POLYGENIC RISK SCORES IMPROVE RISK ASSESSMENT OF CARDIOMETABOLIC COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS	52
POS1118 CLINICAL SIGNIFICANCE OF NON-INFECTIOUS PROCALCITONIN ELEVATION IN THE COURSE OF STILL'S DISEASE	52
POS0022 Long-Term Outcomes in IgA Vasculitis Nephritis Patients: Insights from the Croatian National Center	52
POS1337 CLINICAL OUTCOMES OF METHOTREXATE TREATMENT FOR IMMUNE CHECKPOINT INHIBITOR-INDUCED ARTHRITIS IN CANCER PATIENTS: A RETROSPECTIVE LONGITUDINAL PILOT STUDY	52
POS1206 CLINICAL AND FUNCTIONAL BENEFITS OF EARLY INTRA-ARTICULAR CORTICOSTEROID ADMINISTRATION FOR HIGH-RISK PERSISTENT POST-ARTHROSCOPIC SYNOVITIS	51
POS1133 Upregulation of pro-survival receptors on antibody-secreting cells is linked to worse disease characteristics across SLE, Scleroderma and Sjögrens disease and offers potential new treatment an	51
ABS0707 DO VARIATIONS OF THE 6-MINUTE WALK TEST ACCURATELY REFLECT CHANGES IN CARDIOPULMONARY COMPLICATIONS DURING THE FOLLOW-UP OF PATIENTS WITH SYSTEMIC SCLEROSIS	51
ABS0082 IDENTIFICATION OF CORONARY MORPHOLOGICAL DAMAGE IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES	50
POS1387 DYSREGULATED GENES AND IMMUNE CELL SHIFTS IN OSTEOARTHRITIS HIGHLIGHTING M0 MACROPHAGES, MMP9, AND MAST CELL ACTIVITY	50

ABS1003 ARE MYOSITIS ANTIBODIES MORE COMMON THAN WE KNOW – VERY HIGH PREVALENCE OF ANTI-HMGCR ANTIBODY IN A SINGLE-CENTRE UK COHORT	50
ABS0368 SERUM FERRITIN AS A SPECIFIC BIOMARKER OF ANTI-MDA5-ILD: A MULTICENTER, CASE-CONTROL STUDY IN OBSERVATIONAL AND VALIDATION DATASETS	50
ABS0462 REAL-WORLD OUTCOMES OF BARICITINIB MONOTHERAPY VERSUS csDMARD COMBINATION THERAPY IN RHEUMATOID ARTHRITIS: A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF EFFICACY, SAFETY, AND DRUG RETENTION	50
ABS1158 ISOLATED ANTI-U1-RNP ANTIBODY DETECTED VIA PARTICLE-BASED MULTI-ANALYTE TECHNOLOGY (PMAT): CORRELATION OF TITRE INTENSITY WITH CONNECTIVE TISSUE DISEASES	50
POS1311 VASCULAR EFFECTS OF ACHIEVING LOW DISEASE ACTIVITY IN AXIAL SPONDYLARTHRITIS - A 2-YEAR PROSPECTIVE COHORT STUDY	49
POS1158 ASSESSMENT OF MYOSITIS SPECIFIC ANTIBODIES IN A PRIMARY ARTHRITIS COHORT: SINGLE CENTRE PROSPECTIVE STUDY	49
ABS0750 FIRST USE OF NOVEL BCMA AND CD19 NANOBODY-BASED COMPOUND CAR-T THERAPY TO TARGET B-CELLS AND PLASMA CELLS IN PRECLINICAL STUDY OF AUTOIMMUNE DISEASES	49
POS0007 Reduced Follicular Helper T cells in Peripheral Blood Marks a Distinct Feature of Retroperitoneal Fibrosis	48
OP0180-HPR DOES FOLLOW-UP REALLY MATTER? A MIXED METHODS STUDY EXPLORING PATIENTS' PERSPECTIVES ON FOLLOW-UP SUPPORT IN REHABILITATION ACROSS LEVELS OF CARE	48
POS1460 MAJOR SALIVARY GLAND ULTRASOUND AND ELASTOGRAPHY FOR ASSESSMENT OF DISEASE ACTIVITY IN PATIENTS OF PRIMARY SJÖGREN'S SYNDROME	48
OP0123 AUTOANTIBODIES TO JOINT-RELATED PROTEINS PREDICT REMISSION IN NEW ONSET RA WITH HIGH SPECIFICITY	48
ABS0292 CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME: CLINICAL CHARACTERISTICS AND OUTCOMES. FIVE-YEAR EXPERIENCE	48
POS0877 INTERSTITIAL LUNG DISEASE IN ANTI-U1RNP SYSTEMIC SCLEROSIS PATIENTS: A EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) ANALYSIS	48
POS1437 INTERSTITIAL ANCA-ASSOCIATED VASCULITIS ASSOCIATES WITH SEVERE KIDNEY INJURY INDEPENDENT OF GLOMERULONEPHRITIS	48
OP0209 IMPACT OF CHRONIC INFLAMMATION AND COLLAGEN IV FRAGMENT CANSTATIN ON RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS AND ENDOTHELIAL CELL INTERACTIONS IN VITRO AND IN VIVO	47
POS0128 TEN-YEAR ALL-CAUSE MORTALITY AND RISK FACTORS FOR DEATH IN A LARGE PROSPECTIVE REGISTRY COHORT OF IDIOPATHIC INFLAMMATORY MYOSITIS IN CHINA	47
OP0200 ORAL DELIVERY OF DELTA-9-TETRAHYDROCANNABINOL PROVIDES SYMPTOM AND DISEASE MODIFICATION USING TWO MODELS OF KNEE OSTEOARTHRITIS	47
OP0110 SINGLE CELL RNA-SEQ DISSECTION OF THE SYNOVIAL FLUID IN PSORIATIC ARTHRITIS PATIENTS IDENTIFIES MYELOID CELL SUBSETS RELATED TO TREATMENT RESPONSE WITH BDMARDS	47
POS0429 THE COMPLEMENT SYSTEM AND RESPONSE TO TNF INHIBITION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. POST HOC ANALYSIS FROM CONSUL, A LONGITUDINAL MULTI-CENTER RCT COHORT OF R-AXSPA-PAT	46
OP0243 PROTON PUMP INHIBITOR USE IS ASSOCIATED WITH IMPAIRED BONE MINERAL DENSITY BUT NOT BONE MICROARCHITECTURE IN PATIENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES TAKING GLUCOCORTIC	46
POS0253 FACTORS ASSOCIATED WITH TREATMENT PATHWAYS IN EARLY AXIAL SPONDYLOARTHRITIS: A MULTISTATE ANALYSIS OF THE 10-YEAR FOLLOW-UP OF THE DESIR COHORT	46
POS0215 CLASSIC VERSUS ATYPICAL POLYMYALGIA RHEUMATICA: TWO SIDES OF THE SAME COIN OR MISCLASSIFICATION?	46
POS1369 CHANGES IN PAIN AND REACHING THE PATIENT ACCEPTABLE SYMPTOM STATE IN HAND OSTEOARTHRITIS OVER 4 YEARS	46
POS0042 HIGH-THROUGHPUT TRANSCRIPTOMIC PROFILING OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN AXIAL SPONDYLOARTHRITIS PATIENTS REVEALS CO-EXPRESSED GENE MODULES ASSOCIATED WITH RADIOGRAPHIC DAMAGE	46
POS0165 DETERMINATION OF DISTINCT PHENOTYPES OF PRIMARY SJÖGREN'S DISEASE USING CLUSTER ANALYSIS BASED ON CLINICAL AND BIOLOGICAL MANIFESTATIONS: DATA FROM 458 PATIENTS FROM THE PARIS SACLAY SJÖGREN'S	46
POS0650 FACING THE ISSUES OF CHANGE IN ENTRY VISIT DIAGNOSIS AND LOST OF FOLLOW-UP OVER TIME IN INCEPTION COHORTS: DATA FROM THE AXIAL SPONDYLARTHRITIS (AxSpA) DESIR COHORT	45
POS0919 [18F] POSITRON EMISSION COMPUTED TOMOGRAPHY ([18F] FDG PET/CT) IS ABLE TO PREDICT ULTRASOUND-DEFINED REMISSION IN RHEUMATOID ARTHRITIS	45
POS0841 EFFECTIVENESS AND SAFETY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR TNF-THERAPY IN GERMANY. FINAL RESULTS FROM A POST-MARKETING OBSERVATIONAL STUDY	45
POS0935 THE COURSE OF CYTOKINE AND CHEMOKINE GENE EXPRESSION IN CLINICALLY SUSPECT ARTHRALGIA PATIENTS DURING PROGRESSION TO INFLAMMATORY ARTHRITIS	45
POS1093 WHO ARE THE PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE IN NEED TO SPECIALISED MULTIDISCIPLINARY REHABILITATION?	44
POS0905 AXILLARY ARTERIES ULTRASOUND IN THE DIAGNOSIS OF GIANT CELL ARTERITIS WITH PREDOMINANTLY CRANIAL SYMPTOMS	44
POS1010 MACROPHAGE EXTRACELLULAR TRAPS PROMOTE FIBROBLAST-LIKE SYNOVIOCYTES PROLIFERATION AND PROINFLAMMATORY CYTOKINE IN RHEUMATOID ARTHRITIS	44
POS1152 ATTAINMENT OF EULAR/ERA-EDTA TREATMENT TARGETS IN THE FIRST YEAR IN LUPUS NEPHRITIS: A MULTICENTER OBSERVATIONAL STUDY	43
POS1076 ARE DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS ASSOCIATED WITH A LOWER RISK OF DEMENTIA? A SYSTEMATIC REVIEW WITH META-ANALYSIS	43
POS0913 LOW ADDITIVE VALUE OF A REPEAT MRI EXAMINATION OF THE SACROILIAC JOINTS WHEN THE FIRST MRI IS INCONCLUSIVE	43
POS1131 SECRETAGOGUE EFFECT OF PDE4 INHIBITOR APREMILAST ON HUMAN SALIVARY GLAND ORGANOIDS OBTAINED FROM PRIMARY SJÖGREN'S SYNDROME PATIENTS	43
POS1110 PATIENT CLUSTERS IDENTIFIED BY MACHINE LEARNING: DATA FROM A POOLED ANALYSIS OF PHASE-3 TRIALS OF SECUKINUMAB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS WITH AXIAL	43
AB0110 FEASIBILITY OF AN IL-17A ASSAY IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS	42
POS1468 A HIGH GENETIC RISK OF SLE IS ASSOCIATED WITH AN INCREASED RISK OF MYOCARDIAL INFARCTION AND IMPAIRED KIDNEY FUNCTION; A COMBINED OBSERVATIONAL AND MENDELIAN RANDOMIZATION STUDY	42
AB0131 ASSOCIATION OF CYTOKINE AND CLINICAL EVALUATION BASED ON ULTRASOUND OF SALIVARY GLAND GRADE CLASSIFICATION IN PATIENTS WITH EARLY PRIMARY SJÖGREN'S SYNDROME	42
AB0359 SALIVARY ULTRASONOGRAPHY AND HISTOPATHOLOGIC EVALUATION OF SECONDARY SJÖGREN'S SYNDROME IN RHEUMATOID ARTHRITIS PATIENTS	41
AB0040 DIFFERENCIALLY EXPRESSED GENES IN PATIENTS WITH OSTEOARTHRITIS	41
POS1262 ULTRASONOGRPHIC EVALUATION OF SALIVARY GLANDS IN PATIENTS WITH SYSTEMIC SCLEROSIS	41
POS1481 INFORMING TRIAL MEASUREMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: FREQUENCY OF DOMAIN-SPECIFIC DISEASE ACTIVITY IN A MULTI-NATIONAL OBSERVATIONAL COHORT	41
AB0038 HINDLIMB SUSPENSION INDUCES KNEE MALALIGNMENTS WITH PATELLOFEMORAL OSTEOARTHRITIS IN GROWING RATS	41
AB0771 FEMALE GENDER AND STEROID TREATMENT AS MAIN INFLUENCING FACTORS IN THE PERCEPTION OF QUALITY OF LIFE IN ANCA-ASSOCIATED VASCULITIS: FINAL RESULTS FROM THE ITALIAN VERSION OF ANCA-ASSOCIATED VAS	40
POS1597-HPR ASSESSING THE USE OF VOICE COMMANDS IN THE CLINICAL SETTING	40
AB0070 PIM KYNASES AS POSSIBLE THERAPEUTIC TARGETS IN INFLAMMARORY ARTHRITIDES	40
AB0400 THE PATTERN OF INTERLEUKIN-6 INHIBITORS VERSUS OTHER BIOLOGIC DRUG USE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN WALES, UK: A REAL-WORLD STUDY USING ELECTRONIC HEALTH RECORDS	39
AB0112 IT IS SAFE AND EFFECTIVE TO USE HUMAN CXCL5 TO TREAT MURINE LUPUS	39
AB0349 ENDOCRINE DYSFUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS AND THEIR RELATIONSHIP TO DISEASE SEVERITY	39
AB0082 AGE-RELATED GENES USP2 AND ARG2 ARE INVOLVED IN THE REDUCTION OF IMMUNE CELL INFILTRATION IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS	39
AB1148 PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF PSORIATIC ARTHRITIS APPEAR MORE IN AGREEMENT IN ARAB COUNTRIES THAN PREVIOUSLY REPORTED ELSEWHERE – AN INTERNATIONAL STUDY UNDER THE AEGIS OF ARLAR	39
AB0216 INHIBITION OF RADIOGRAPHIC JOINT DAMAGE BY JAK INHIBITORS IN PATIENTS WITH DESTRUCTIVE RHEUMATOID ARTHRITIS WITH EXTENSIVE BONE MARROW EDEMA IN HAND	39
AB0675 AVASCULAR NECROSIS IN A COHORT OF SLE PATIENTS IN AN AFRICAN CONTEXT	38
AB0406 EFFICACY OF TNF-ALPHA INHIBITORS IN MANAGEMENT OF IMMUNE CHECKPOINT INHIBITOR RELATED ARTHRITIS	38
AB0763 CHARACTERISTICS OF RELAPSES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. A SINGLE CENTRE EXPERIENCE	37
AB1339 EFFICACY AND SAFETY OF THE SARS-CoV-2 VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS	37
AB0693 IN-OFFICE LACRIMAL BIOMARKERS IN PRIMARY SJÖGREN'S SYNDROME	37
AB0174 EXPLORING A POTENTIAL ANTI-TUMOR IMMUNE MICROENVIRONMENT IN GIANT CELL ARTERITIS	37
AB0685 DESCRIPTIVE STUDY OF A COHORT OF PATIENTS WITH NEUROPSYCHIATRIC MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS IN A TERTIARY HOSPITAL	37
AB0297 FOOT AND ANKLE INVOLVEMENT IN RHEUMATOID ARTHRITIS IS ASSOCIATED WITH DISEASE ACTIVITY AND LESS INTENSIVE TREATMENT	36
AB0677 CUT OFF POINT OF NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A MARKER OF DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AT HAJ ALSAFFE HOSPITAL LUPUS CLINIC FROM JUNE 2021 TO SEPTEMBER 2021	36
AB0180 PAIN SENSITISATION IN FIBROMYALGIA. THE CROSS-SECTIONAL ASSOCIATIONS BETWEEN MEASURES OF QUANTITATIVE SENSORY TESTING AND FIBROMYALGIA SEVERITY	36
AB1047 COMORBIDITY WITH FIBROMYALGIA IS ASSOCIATED WITH INCREASED JOINT SWELLING, HIGH DISEASE ACTIVITY AND REDUCED PRODUCTIVITY IN THAI PATIENTS WITH SPONDYLOARTHRITIS	35
AB0819 CLINICAL AND IMMUNOLOGICAL PROFILES OF PATIENTS WITH ANTI-SYNTHETASE SYNDROME: A RETROSPECTIVE COHORT STUDY FROM A TERTIARY CENTRE	35
AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM	35
AB0846 EFFICACY OF RITUXIMAB IN IDIOPATHIC INFLAMMATORY MYOPATHIES. EXPERIENCE ON 36 PATIENTS FROM A PROSPECTIVE MONOCENTRIC COHORT	35
AB0591 COVID-19 VACCINE SAFETY DURING PREGNANCY IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS	35
AB1595 HOW DO WE PREVENT THE DEVELOPMENT OF MULTIMORBIDITY IN PEOPLE WITH INFLAMMATORY RHEUMATOLOGICAL DISORDERS: A QUALITATIVE INVESTIGATION	35
AB0783 RISK FACTORS IN HENOCH-SCHӦNLEIN PURPURA NEPHRITIS	35
AB0964 THERAPEUTIC DRUG MONITORING OF INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES: REAL-LIFE DATA IN A COHORT OF PATIENTS	34
AB1436 BIOLOGIC THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS TUNISIAN PATIENTS	34
AB1294 SAFETY OF COVID-19 VACCINES AND HEALTH CARE UTILIZATION FOLLOWING VACCINATION AMONG ADULTS WITH RHEUMATOID ARTHRITIS – A POPULATION-BASED SELF-CONTROLLED CASE SERIES ANALYSIS	34
AB0840 ACUTE VASCULAR EFFECTS OF INTRAVENOUS ILOPROST IN SCLERODERMA PATIENTS CAN BE DETECTED BY POWER DOPPLER EXAMINATION OF THE FINGER SUBCUTANEOUS TISSUE	34
AB1222 NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) PREDICTS FRACTURE IN PATIENTS ON LONG-TERM GLUCOCORTICOID.	34
AB0667 CHARACTERIZING ULTRASOUND-PROVEN ENTHESITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS: PREVALENCE AND IDENTIFICATION OF DISEASE SUBSET WITH LESS FREQUENT RENAL INVOLVEMENT	34
AB1410 ASSOCIATION BETWEEN MUSCLE MASS PERCENTAGE WITH PAIN AND DISABILITY IN PATIENTS WITH NON-SPECIFIC CHRONIC LOW BACK PAIN: THE BACKFIT PROJECT	34
AB1351 FREQUENCY OF VACCINE-RELATED ADVERSE EVENTS IN PATIENTS WITH RHEUMATIC DISEASE	33
AB1694 IN VIVO MEASUREMENT OF POTENT AND DURABLE HUMAN ADIPOSE 11Β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITION BY SPI-62	33
AB1729-PARE BEING “THE HEALTHY ONE”: THE HARD LIVING WITH A SICK BROTHER/SISTER	33
AB1217 COMORBIDITIES DURING GONARTHROSIS	33
AB1291 COVID-19 AND CRYOGLOBULINEMIC VASCULITIS.LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT'S POPULATION	33
AB1054 SPONDYLOARTHRITIS IN FIRST DEGREE RELATIVES OF ANKYLOSING SPONDYLITIS PATIENTS	33
AB1285 MODELING OF ANTIBODY RESPONSE TO COVID-19 VACCINATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS	33
AB1709 AWARENESS OF EDUCATIONAL AND RESEARCH OFFERINGS OF EULAR AND EMEUNET AMONG YOUNG RHEUMATOLOGISTS WORKING IN TURKEY	32
OP0295-HPR THE EFFECT OF GROUP-BASED COGNITIVE BEHAVIOURAL THERAPY FOR INSOMNIA IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED TRIAL	32
AB1487 EFFECTIVENESS OF RITUXIMAB IN IGG4-RELATED DISEASE. MULTICENTRE STUDY AND LITERATURE REVIEW	32
AB0737 Capillaroscopic patterns in patients with Systemic Sclerosis- Rheumatoid arthritis (SSc-RA) overlap syndrome. \| Annals of the Rheumatic Diseases	32
POS1406 THE EFFECTS AND MOLECULAR MECHANISMS OF TRAF5 ON PULMONARY ARTERY ENDOTHELIAL CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION	32
POS0020 PAIN PHENOTYPING IN PATIENTS WITH PSORIATIC ARTHRITIS AND HAND OSTEOARTHRITIS	32
AB0078 NESFATIN-1 EXPRESSION ASSOCIATED WITH A MARKER FOR BONE MATRIX FORMATION P1NP IN RHEUMATOID ARTHRITIS	31
POS0182 WHO ARE LIKELY TO BENEFIT FROM THE GOOD LIFE WITH OSTEOARTHRITIS IN DENMARK (GLAD) EXERCISE AND EDUCATION PROGRAM? AN EFFECT MODIFIER ANALYSIS OF A RANDOMISED CONTROLLED TRIAL	31
POS0251 TRANSCRIPTOMIC CHANGES INDUCED BY MAVRILIMUMAB VERSUS TOCILIZUMAB IN EX-VIVO CULTURED ARTERIES FROM PATIENTS WITH GIANT-CELL ARTERITIS	31
POS0185 BELIMUMAB DISRUPTS MEMORY B-CELL TRAFFICKING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	31